Five adverts by online healthcare provider Voy have been banned by the Advertising Standards Authority for making misleading claims linked to low testosterone in men, including linking common symptoms such as irritability and fatigue to the condition.
The ASA said the adverts, which appeared as three posters and two paid-for Facebook ads, promoted Voy’s at-home testosterone blood tests. It said some of the adverts “exaggerated the connection between several common symptoms, which can have many possible causes, and low testosterone.”
The watchdog gave examples of symptoms such as low sex drive, low energy, loss of motivation and changes in mood. It said that while some symptoms may be more closely associated with low testosterone, "others were much less specific and shouldn't have been presented as strong indicators of low testosterone in isolation."
ASA also objected to one Facebook advert that claimed "low testosterone sneaks up on 1 in 4 men over 30", saying it was misleading and not supported by the evidence Voy provided.
Voy, a company that sells products such as testosterone, menopause and weight loss treatments, said it had withdrawn the adverts while the investigation was under way and would not run them again. The company's chief medical officer, Dr Earim Chaudry, said: "Every patient decision at Voy is clinician-led and these campaigns were developed to align with UK advertising standards. We keep all our advertising under continual review to ensure it meets any updated guidance."
The ruling follows two others in August by the ASA, which found misleading claims in adverts for testosterone testing services from online providers BioID Health and Numan Digital Healthcare. The ASA said it had identified a "recurring theme of advertisers playing on insecurities around libido, erectile problems, testosterone and ageing" in adverts aimed at men concerned about their health.
The watchdog said adverts for tests and services relating to low testosterone were allowed, but businesses needed to ensure the claims they made were accurate and supported by evidence.
Some of Voy's testosterone test kit adverts drew a backlash online earlier this year when they appeared on the London Underground. Some described them as "ragebait" for using phrases such as "It's not him, it's his hormones" and "Men get hormonal too". At the time Voy said it was trying to destigmatise conversations about men's health.
Analysis
Why This Matters
- The ruling sets a precedent for how online healthcare providers can market testosterone tests, requiring claims to be backed by solid evidence.
- It highlights a broader regulatory crackdown on adverts that target men's health insecurities, potentially affecting how such services are promoted across the UK.
- Patients may be misled into seeking unnecessary treatment for low testosterone when their symptoms have other causes, leading to wasted time and money.
Background
Testosterone levels naturally decline as men age. The NHS states that this is "unlikely" to cause any problems in itself. While a deficiency can sometimes cause symptoms such as depression, loss of sex drive and erectile dysfunction, these are often not linked to testosterone. The ASA has been investigating adverts aimed at men's health concerns, having already banned similar ads from BioID Health and Numan Digital Healthcare in August.
Key Perspectives
Advertising Standards Authority: The adverts exaggerated the link between common symptoms and low testosterone; the claim that low testosterone affects 1 in 4 men over 30 was not supported by evidence.
Voy (Dr Earim Chaudry, chief medical officer): The campaigns were developed to align with UK advertising standards and the company keeps its advertising under review.
Dr Richard Quinton (testosterone deficiency expert): It is easy to get a low testosterone reading in a healthy man simply by doing a blood test at the wrong time of day or when unwell.
What to Watch
- Whether Voy or other providers face further ASA investigations over other adverts.
- Whether the ASA expands its investigation to other areas of men's health advertising, such as erectile dysfunction treatments.
- How online healthcare companies adjust their marketing strategies to comply with the regulator's findings.
Checked
12 claims in this story checked against 1 source: 12 supported.
Show each claim
- SupportedVoy’s at-home test kit adverts were banned over misleading low-testosterone claims.BBC News: “Five adverts by online healthcare provider Voy have been banned by the watchdog for making misleading claims linked to low testosterone in men.”
- SupportedThe watchdog said some ads exaggerated links between common symptoms and low testosterone.BBC News: “The ASA's ruling, however, took issue with how some of the adverts "exaggerated the connection between several common symptoms, which can have many possible causes, and low testosterone".”
- SupportedFive Voy adverts were banned.BBC News: “Five adverts by online healthcare provider Voy have been banned by the watchdog”
- SupportedThe adverts promoted Voy’s at-home testosterone blood tests and comprised three posters and two paid-for Facebook ads.BBC News: “The Advertising Standards Authority (ASA) said the adverts promoted Voy's at-home testosterone blood tests in three posters and two paid-for Facebook ads.”
- SupportedThe ads linked common symptoms including irritability and fatigue to low testosterone.BBC News: “It said they were misleading as they linked common symptoms such as irritability and fatigue to low testosterone.”
- SupportedThe ASA said some symptoms can have many possible causes and should not be presented as strong indicators of low testosterone in isolation.BBC News: “"While some symptoms may be more closely associated with the condition, others were much less specific and shouldn't have been presented as strong indicators of low testosterone in isolation," the watchdog said.”
- SupportedOne Facebook ad claimed that low testosterone “sneaks up on 1 in 4 men over 30”; the ASA said the claim was misleading and unsupported by the evidence Voy provided.BBC News: “It added that one of the Facebook adverts also included the claim that "low testosterone sneaks up on 1 in 4 men over 30". The ASA said this was misleading and not supported by the evidence provided by Voy.”
- SupportedVoy said it withdrew the adverts during the investigation and would not run them again.BBC News: “Voy said it had withdrawn the adverts while the investigation was under way and would not run them again.”
- SupportedVoy chief medical officer Dr Earim Chaudry said the campaigns were developed to align with UK advertising standards and that the company continually reviewed its advertising.BBC News: “Dr Earim Chaudry, chief medical officer for Voy, said: "Every patient decision at Voy is clinician-led and these campaigns were developed to align with UK advertising standards. We keep all our advertising under continual review to ensure it meets any updated guidance."”
- SupportedThe ruling followed two ASA rulings in August concerning ads for testosterone testing services from BioID Health and Numan Digital Healthcare.BBC News: “Wednesday's ruling followed two others in August by the watchdog, which found misleading claims in adverts for testosterone testing services from online providers BioID Health and Numan Digital Healthcare.”
- SupportedThe ASA identified a recurring theme of advertisers playing on insecurities around libido, erectile problems, testosterone and ageing.BBC News: “This has identified a "recurring theme of advertisers playing on insecurities around libido, erectile problems, testosterone and ageing", the regulator said.”
- SupportedSome Voy testosterone test kit adverts appeared on the London Underground earlier in the year and drew online backlash; Voy said it was trying to destigmatise conversations about men’s health.BBC News: “Some of its testosterone test kit adverts drew a backlash online earlier this year when they appeared on the London Underground. Some described them as "ragebait" for using phrases such as "It's not him, it's his hormones" and "Men get hormonal too". At the time Voy said it was trying to destigmatise conversations about men's health.”